inclusion criteria: a. adult males or females (≥ 18 years of age), not hospitalized, diagnosed with sars-cov-2 infection by oropharyngeal rt-pcr or swab antigen test, with mild symptoms of infection. b. symptomatic subjects must have at least 1 of the following symptoms at inclusion: fever or fever perceived for more than 24 hours, headache, sore throat, nasal obstruction, dry cough, fatigue, chest pain, or choking sensation (no associated respiratory distress ), myalgia, anosmia, ageusia or gastrointestinal symptoms within 10 days of onset; c. subjects with arterial pulse oximetry (spo2) saturation ≥ 92% in room air at inclusion; d. participants with the following hematological and biochemical laboratory parameters obtained within 7 days before d0: * hemoglobin \> 9.0 g/dl-1 * absolute neutrophil count ≥ 1000 mm-³ * platelets ≥ 100,000 mm-3 * creatinine clearance ≥ 30 ml/min-1 by cockcroft-gault formula * rapid negative pregnancy test for women of childbearing age. and. participants must understand, sign and date the voluntary written consent form at the visit prior to any protocol-specific procedure; e. participants must be able and willing to comply with study visits and procedures as per protocol.

inclusion criteria: a. adult males or females (≥ 18 years of age), not hospitalized, diagnosed with sars-cov-2 infection by oropharyngeal rt-pcr or swab antigen test, with mild symptoms of infection. b. symptomatic subjects must have at least 1 of the following symptoms at inclusion: fever or fever perceived for more than 24 hours, headache, sore throat, nasal obstruction, dry cough, fatigue, chest pain, or choking sensation (no associated respiratory distress ), myalgia, anosmia, ageusia or gastrointestinal symptoms within 10 days of onset; c. subjects with arterial pulse oximetry (spo2) saturation ≥ 92% in room air at inclusion; d. participants with the following hematological and biochemical laboratory parameters obtained within 7 days before d0: * hemoglobin \> 9.0 g/dl-1 * absolute neutrophil count ≥ 1000 mm-³ * platelets ≥ 100,000 mm-3 * creatinine clearance ≥ 30 ml/min-1 by cockcroft-gault formula * rapid negative pregnancy test for women of childbearing age. and. participants must understand, sign and date the voluntary written consent form at the visit prior to any protocol-specific procedure; e. participants must be able and willing to comply with study visits and procedures as per protocol.

inclusion criteria: a. adult males or females (≥ 18 years of age), not hospitalized, diagnosed with sars-cov-2 infection by oropharyngeal rt-pcr or swab antigen test, with mild symptoms of infection. b. symptomatic subjects must have at least 1 of the following symptoms at inclusion: fever or fever perceived for more than 24 hours, headache, sore throat, nasal obstruction, dry cough, fatigue, chest pain, or choking sensation (no associated respiratory distress ), myalgia, anosmia, ageusia or gastrointestinal symptoms within 10 days of onset; c. subjects with arterial pulse oximetry (spo2) saturation ≥ 92% in room air at inclusion; d. participants with the following hematological and biochemical laboratory parameters obtained within 7 days before d0: hemoglobin > 9.0 g/dl-1 absolute neutrophil count ≥ 1000 mm-³ platelets ≥ 100,000 mm-3 creatinine clearance ≥ 30 ml/min-1 by cockcroft-gault formula rapid negative pregnancy test for women of childbearing age. and. participants must understand, sign and date the voluntary written consent form at the visit prior to any protocol-specific procedure; e. participants must be able and willing to comply with study visits and procedures as per protocol.

inclusion criteria: a. adult males or females (≥ 18 years of age), not hospitalized, diagnosed with sars-cov-2 infection by oropharyngeal rt-pcr or swab antigen test, with mild symptoms of infection. b. symptomatic subjects must have at least 1 of the following symptoms at inclusion: fever or fever perceived for more than 24 hours, headache, sore throat, nasal obstruction, dry cough, fatigue, chest pain, or choking sensation (no associated respiratory distress ), myalgia, anosmia, ageusia or gastrointestinal symptoms within 10 days of onset; c. subjects with arterial pulse oximetry (spo2) saturation ≥ 92% in room air at inclusion; d. participants with the following hematological and biochemical laboratory parameters obtained within 7 days before d0: hemoglobin > 9.0 g/dl-1 absolute neutrophil count ≥ 1000 mm-³ platelets ≥ 100,000 mm-3 creatinine clearance ≥ 30 ml/min-1 by cockcroft-gault formula rapid negative pregnancy test for women of childbearing age. and. participants must understand, sign and date the voluntary written consent form at the visit prior to any protocol-specific procedure; e. participants must be able and willing to comply with study visits and procedures as per protocol.

inclusion criteria: a. adult males or females (≥ 18 years of age), not hospitalized, diagnosed with sars-cov-2 infection by oropharyngeal rt-pcr or swab antigen test, with mild symptoms of infection. b. symptomatic participants must have at least 1 of the following symptoms at inclusion: fever or fever perceived for more than 24 hours, headache, sore throat, nasal obstruction, dry cough, fatigue, chest pain, or choking sensation (no associated respiratory distress ), myalgia, anosmia, ageusia or gastrointestinal symptoms within 10 days of onset; c. participants with arterial pulse oximetry (spo2) saturation ≥ 92% in room air at inclusion; d. participants with the following hematological and biochemical laboratory parameters obtained within 7 days before d0: hemoglobin > 9.0 g/dl-1 absolute neutrophil count ≥ 1000 mm-³ platelets ≥ 100,000 mm-3 creatinine clearance ≥ 30 ml/min-1 by cockcroft-gault formula rapid negative pregnancy test for women of childbearing age. and. participants must understand, sign and date the voluntary written consent form at the visit prior to any protocol-specific procedure; f. participants must be able and willing to comply with study visits and procedures as per protocol.

inclusion criteria: a. adult males or females (≥ 18 years of age), not hospitalized, diagnosed with sars-cov-2 infection by oropharyngeal rt-pcr or swab antigen test, with mild symptoms of infection. b. symptomatic participants must have at least 1 of the following symptoms at inclusion: fever or fever perceived for more than 24 hours, headache, sore throat, nasal obstruction, dry cough, fatigue, chest pain, or choking sensation (no associated respiratory distress ), myalgia, anosmia, ageusia or gastrointestinal symptoms within 10 days of onset; c. participants with arterial pulse oximetry (spo2) saturation ≥ 92% in room air at inclusion; d. participants with the following hematological and biochemical laboratory parameters obtained within 7 days before d0: hemoglobin > 9.0 g/dl-1 absolute neutrophil count ≥ 1000 mm-³ platelets ≥ 100,000 mm-3 creatinine clearance ≥ 30 ml/min-1 by cockcroft-gault formula rapid negative pregnancy test for women of childbearing age. and. participants must understand, sign and date the voluntary written consent form at the visit prior to any protocol-specific procedure; f. participants must be able and willing to comply with study visits and procedures as per protocol.